ACRV Earnings Acrivon Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–19 of 19
| Q1 2026 | 2026-03-31 | -0.49 | 2026-05-13 | 10-Q |
| FY 2025 | 2025-12-31 | -2.02 | 2026-03-19 | 10-K |
| Q3 2025 | 2025-09-30 | -1.53 | 2025-11-13 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.06 | 2025-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.51 | 2026-05-13 | 10-Q |
| FY 2025 | 2024-12-31 | -2.38 | 2026-03-19 | 10-K |
| Q3 2025 | 2024-09-30 | -1.79 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.20 | 2025-08-13 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.73 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -2.74 | 2025-03-27 | 10-K |
| Q3 2024 | 2023-09-30 | -1.87 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.22 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.58 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -7.56 | 2024-03-28 | 10-K |
| Q3 2023 | 2022-09-30 | -12.55 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -7.37 | 2023-08-11 | 10-Q |
| Q1 2023 | 2022-03-31 | -4.08 | 2023-05-09 | 10-Q |
| FY 2022 | 2021-12-31 | -9.32 | 2023-03-28 | 10-K |
| Q3 2022 | 2021-09-30 | -6.86 | 2022-12-15 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.